Premium
Ligands of the peroxisome proliferator‐activated receptor‐ γ and heart failure
Author(s) -
Thiemermann Christoph
Publication year - 2004
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705898
Subject(s) - nuclear receptor , peroxisome proliferator activated receptor , receptor , peroxisome , ppar agonist , transcription factor , thyroid hormone receptor , hormone , pharmacology , peroxisome proliferator activated receptor alpha , chemistry , endocrinology , medicine , biochemistry , gene
This Commentary originally appeared in the British Journal of Pharmacology in January 2004 ( Br J Pharmacol 141 (1), 1–3). That version, regrettably, contained a number of errors and the corrected version is printed here, as an Erratum. Peroxisome proliferator‐activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand‐activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors. The PPAR subfamily comprises of three members, PPAR‐ α , PPAR‐ β and PPAR‐ γ . There is good evidence that ligands of PPAR‐ γ , including certain thiazolinediones, reduce myocardial tissue injury and infarct size. The use of PPAR‐ γ agonists in the treatment of heart failure is, however, controversial. British Journal of Pharmacology (2004) 142 , 1049–1051. doi: 10.1038/sj.bjp.0705898